20-NOV-2024 6:10

LEUK ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/
Support		 STUDY R
E
G		 O
P
E
N		 ARM ACCR.
GOAL		 TOTAL
REGS.		 REGS.
LAST
12
Month		 REGS.
LAST
6
Month		 REGS.
LAST
3
Month		 REGS.
LAST
30
DAYS		 REGS.
LAST
7
DAYS		 DATE OF
FIRST
REG.		 # of
ACT.
INSTs		 # of
CURR
IRBs
SWOG S1905-T-ALL/T-LBL, Rel/Ref, OBI-3424 1 Y 1 OBI-3424 8mg 64 5 0 0 0 0 0 02/08/2021 58 23
        2 OBI-3424 10mg   5 0 0 0 0 0      
        3 OBI-3424 12mg   8 4 3 1 0 0      
            18 4 3 1 0 0      
 
  S1925-CLL/SLL, Newly Dx HR, Early vs Delayed V+O 1 Y 1 Delayed V-O 247 41 12 5 2 0 0 03/02/2021 251 98
        2 Early V-O   79 25 12 6 2 1      
            120 37 17 8 2 1      
 
  MM1YA-S01-AML, High Risk, Age <60, 7+3 vs experimental 1 Y 2 Venetoclax + Daunorubicin + Cytarabine 335 1 1 1 1 1 1 09/25/2024 158 62
        3 Venetoclax + Azacitidine   1 1 1 1 0 0      
        4 (Daunorubicin + Cytarabine) Liposome   1 1 1 1 0 0      
        5 (Daunorubicin + Cytarabine) Liposome + Venetoclax   1 1 1 1 0 0      
            4 4 4 4 1 1      
 
  MYELOMATCH-MSRP for the NCI myeloMATCH Clinical Trials 1 Y 1 Screening   120 120 120 111 43 11 06/18/2024 226 93
            120 120 120 111 43 11      
 
    2 Y 2 Re-screening   4 4 4 4 4 3 06/18/2024    
            4 4 4 4 4 3      
 
Yes A042001-B-Cell ALL, Inotuzunab+chemo v Standard chemo 0 E Total Registrations   7 5 5 4 0 0 10/12/2023 137 47
            7 5 5 4 0 0      
 
    1 E Total Registrations   6 4 4 3 0 0 10/12/2023    
            6 4 4 3 0 0      
 
  EA9213-T-ALL, dara-hyal for chemo refractory MRD 0 E Total Registrations   5 1 0 0 0 0 02/24/2023 54 17
            5 1 0 0 0 0      
 
    1 E Total Registrations   3 1 0 0 0 0 02/24/2023    
            3 1 0 0 0 0      
 
No A041501-B-Cell ALL, Frontline Tx +/- Intuzumab Ozo 0 E Total Registrations   71 0 0 0 0 0 11/09/2018 240 85
            71 0 0 0 0 0      
 
    1 E Total Registrations   57 0 0 0 0 0 11/09/2018    
            57 0 0 0 0 0      
 
    2 E Total Registrations   44 0 0 0 0 0 11/09/2018    
            44 0 0 0 0 0      
 
  A041703-ALL, Newly Dx, Inotuzumab Ozogamicin + Blinat 0 E Total Registrations   11 1 0 0 0 0 08/13/2020 134 54
            11 1 0 0 0 0      
 
    1 E Total Registrations   5 1 0 0 0 0 08/13/2020    
            5 1 0 0 0 0      
 
  EA9171-CML, Anti-PD-1 Pembrolizumab + TKIs 0 E Total Registrations   4 1 0 0 0 0 02/18/2020 64 34
            4 1 0 0 0 0      
 
    1 E Total Registrations   4 1 0 0 0 0 02/18/2020    
            4 1 0 0 0 0      
 
    2 E Total Registrations   1 0 0 0 0 0 02/18/2020    
            1 0 0 0 0 0      
 
  EA9181-ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab 0 E Total Registrations   46 11 7 1 1 1 02/19/2021 175 60
            46 11 7 1 1 1      
 
    1 E Total Registrations   37 7 4 0 0 0 02/19/2021    
            37 7 4 0 0 0      
 
    2 E Total Registrations   33 6 4 1 0 0 02/19/2021    
            33 6 4 1 0 0      
 
  MM1YACTG01-AML, New/Young/Intermediate, Ven+Chemo 1 E Total Registrations   2 2 2 2 0 0 10/14/2024 133 42
            2 2 2 2 0 0      
 

20-NOV-2024 6:10

LEUK Open Studies with No Registrations

Study Registration/Phase Open Date # of
ACT.
INSTs		 # of
CURR
IRBs
EA9181 ALL, BCR-ABL+, Steroids+TKI+CT/Blinatumomab 3 Randomization 14-Oct-20 175 60
MYELOMATCH MSRP for the NCI myeloMATCH Clinical Trials 3 Re-screening 16-May-24 226 93
  4 Re-screening 16-May-24 226 93